Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent

View source ↗

Summary

This document reports the completion and posting of results from an observational study evaluating Rituximab (MabThera/Rituxan) in rheumatoid arthritis patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (MabThera / Rituxan) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2016-08-17